CG Oncology valued at $1.75 bln in strong market debut - Nasdaq

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as demand for new …

CouponFollow Extension

6%
OFF

CG Oncology Valued At $1.75 Bln In Strong Market Debut - Nasdaq

21 hours ago

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as demand for new …

nasdaq.com

6%
OFF

Cancer Drug Developer CG Oncology Valued At $1.75 Bln In Strong …

21 hours ago

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

reuters.com

6%
OFF

UPDATE 2-Cancer Drug Developer CG Oncology Valued At $1.75 …

21 hours ago

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

yahoo.com

6%
OFF

CG Oncology Valued At $1.75 Bln In Strong Market Debut - Yahoo …

21 hours ago

CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the cancer drug developer rose 52.6% at the open on the Nasdaq.

yahoo.com

$1.75
OFF

CG Oncology, Inc. (CGON) Stock Price, Quote & News - Stock …

21 hours ago

5 days ago · CG Oncology valued at $1.75 bln in strong market debut. CG Oncology CGON.O notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the …

stockanalysis.com

6%
OFF

CG Oncology Inc | Reuters

21 hours ago

Feb 9, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

reuters.com

6%
OFF

CG Oncology Valued At $1.75 Bln In Strong Market Debut

21 hours ago

Jan 25, 2024 · CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the cancer drug developer rose 52.6% at the open on the Nasdaq. ...

marketscreener.com

96%
OFF

CG Oncology IPO Rockets 96% In Sign Of Pent-up Deal Demand

21 hours ago

Jan 25, 2024 · CG Oncology's debut marked the latest sign of a revival in the IPO market after a lack of deals in 2023. ... Signs of a strong IPO for CG Oncology came late Wednesday, when …

morningstar.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO | Nasdaq

21 hours ago

Jan 18, 2024 · Adds details on company's business, IPO terms in paragraphs 2-6. Jan 18 (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation …

nasdaq.com

$2.29
OFF

Cg Oncology Stock Price Today (NASDAQ: CGON) Quote, Market …

21 hours ago

3 days ago · (NASDAQ: CGON) Cg Oncology's market cap is $2.29B, as of Nov 27, 2024. Market cap (market capitalization) is the total market value of a publicly traded company's outstanding …

wallstreetzen.com

$1
OFF

UPDATE 1-CG Oncology Targets Near $1 Bln Valuation In US IPO

21 hours ago

Jan 18, 2024 · (Adds details on company's business, IPO terms in paragraphs 2-6) Jan 18 (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation …

yahoo.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO | Reuters

21 hours ago

Jan 18, 2024 · Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering.

reuters.com

FAQs about CG Oncology valued at $1.75 bln in strong market debut - Nasdaq Coupon?

How much is CG oncology worth?

Jan 25 (Reuters) - Cancer drug developer CG Oncology (CGON.O) notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up pace. ...

Is CG oncology a good IPO?

Biotech stocks have fallen about 1% so far this year. With a lead asset in advanced Phase-III testing, CG Oncology, which debuts Thursday on the NASDAQ, is one of the year's most highly anticipated IPOs. The company's lead drug targets a sizable addressa... ...

How did CG oncology raise $380 million?

The firm sold 20 million shares in its offering and raised $380 million. CG Oncology's initial public offering (IPO), the first by a biotech firm this year, sets the stage for other healthcare companies such as KKR-backed BrightSpring Health Services and Moderna-backed Metagenomi. ...

Who are CG oncology's biggest shareholders?

Biotech investor ORI Capital and life sciences investor Decheng Capital are its biggest shareholders. CG Oncology is one of a handful of companies from the healthcare sector looking to list in the coming months, as a market rally on hopes of a soft landing for the economy eases pressure on startups looking to go public. ...

Will CG Oncology GO Public?

The firm aims to list on the Nasdaq under the symbol CGON. CG Oncology has filed to go public with an IPO on the NASDAQ. CG Oncology has received fast track designation and breakthrough designation needed to accelerate US FDA submission. ...

How effective is CG oncology's bladder cancer molecule cretostimogene?

CG Oncology's bladder cancer molecule, cretostimogene, showed high success with a 75.2% complete response rate in a phase 3 monotherapy study. Cretostimogene, an oncolytic immunotherapy, works by sele... ...